Novo Nordisk, maker of Ozempic, applied for FDA approval for a weight loss pill, less than a week after rival Eli Lilly's clinical trial success.

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for ...

Eli Lilly gains ground with Orforglipron’s success, showing growth potential and risks from momentum and tariffs. Read why ...

Shares of Eli Lilly jumped 16% Thursday morning after the pharmaceutical company released clinical trial results for its oral ...

Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment ...

People diagnosed with type 2 diabetes might benefit soon from Eli Lilly's new orforglipron weight loss drug following its ...

Representatives from Lilly said the company plans to seek FDA approval to market the drug for weight loss this year and diabetes in 2026. The FDA’s review could take months, yet analysts ...

Drugmaker Eli Lilly (NYSE: LLY) hasn't been exempt from the recent market pullback, but its stock shot higher following the ...

In a trial, the daily GLP-1 pill showed "significant" results and similar side effects to injectable GLP-1 drugs like Ozempic ...

“I’m actually ok with a little weight gain," the former Playboy star said Steve Kondiles/Bauer-Griffin/GC Images Kendra Wilkinson said she tried a weight-loss drug but stopped after one ...

It's little secret that America has a weight problem. For decades, Americans have embraced and abandoned countless ...